Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists

References

• ConnJWPrimary aldosteronismJ Lab Clin Med195545466166414368032
   PubMed Web of Science ®Google Scholar
• GordonRDFishmanLMLiddleGWPlasma renin activity and aldosterone secretion in a pregnant woman with primary aldosteronismJ Clin Endocrinol Metab19672733853885337160
   PubMed Web of Science ®Google Scholar
• FishmanLMKüchelOLiddleGWMichelakisAMGordonRDChickWTIncidence of primary aldosteronism uncomplicated “essential” hypertension: a prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteriaJAMA196820574975025695306
   PubMed Web of Science ®Google Scholar
• MarsenBDissmannTOelkersWLohmannFWMolzahnMGotzenREndocrinologic and circulatory findings in a case of primary aldosteronismDtsch Med Wochenschr19719622951954 German5578596
   PubMed Web of Science ®Google Scholar
• RossiCAEcheverriaHPrimary aldosteronismPrensa Med Argent19715715777782 Spanish5094920
   PubMedGoogle Scholar
• LaraghJHHormonal profiling in the diagnosis and treatment of essential hypertensionDel Med J19744631251334361408
   PubMedGoogle Scholar
• McCaaCSLangfordHGCushmanWCMcCaaREResponse of arterial blood pressure, plasma renin activity and plasma aldosterone concentration to long-term administration of captopril in patients with severe, treatment-resistant malignant hypertensionClin Sci (Lond)197957Suppl 5371s373s396084
   PubMedGoogle Scholar
• LaraghJHLetcherRLPickeringTGRenin profiling for diagnosis and treatment of hypertensionJAMA1979241215115631492
   PubMed Web of Science ®Google Scholar
• LimRCJrNakayamaDKBiglieriEGSchambelanMHuntTKPrimary aldosteronism: changing concepts in diagnosis and managementAm J Surg198615211161213728804
   PubMed Web of Science ®Google Scholar
• GriffingGTWilsonTEMelbyJCAlterations in aldosterone secretion and metabolism in low renin hypertensionJ Clin Endocrinol Metab1990716145414602229301
   PubMed Web of Science ®Google Scholar
• GordonRDStowasserMTunnyTJKlemmSAFinnWLKrekALClinical and pathological diversity of primary aldosteronism, including a new familial varietyClin Exp Pharmacol Physiol19911852832862065471
   PubMed Web of Science ®Google Scholar
• GordonRDStowasserMTunnyTJKlemmSARutherfordJCHigh incidence of primary aldosteronism in 199 patients referred with hypertensionClin Exp Pharmacol Physiol19942143153187923898
   PubMed Web of Science ®Google Scholar
• LimPOYoungWFMacDonaldTMA review of the medical treatment of primary aldosteronismJ Hypertens200119335336111288803
   PubMed Web of Science ®Google Scholar
• LimPOMacDonaldTMPrimary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertensionClin Endocrinol (Oxf)200359442743014510903
   PubMed Web of Science ®Google Scholar
• ConnJWCohenELRovnerDRNesbitRMNormokalemic primary aldosteronism: a detectable cause of curable “essential” hypertensionJAMA1965193320020614310325
   PubMed Web of Science ®Google Scholar
• PessinaACSacchettoARossiGPLeft ventricular anatomy and function in primary aldosteronism and renovascular hypertensionZanchettiADevereuxRBHanssonLGoriniSHypertension and the HeartHeidelbergSpringer19976369
   Google Scholar
• MackenzieSMConnellJHypertension and the expanding role of aldosteroneCurr Hypertens Rep20068325526117147925
   PubMed Web of Science ®Google Scholar
• DuprezDABauwensFRDe BuyzereMLInfluence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertensionAm J Cardiol199371317A20A
   PubMed Web of Science ®Google Scholar
• BlacherJAmahGGirerdXAssociation between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertensionAm J Hypertens19971012 Pt 1132613349443767
   PubMed Web of Science ®Google Scholar
• RochaRStierCTJrKiforIAldosterone: a mediator of myocardial necrosis and renal arteriopathyEndocrinology2000141103871387811014244
   PubMed Web of Science ®Google Scholar
• El-GharbawyAHNadigVSKotchenJMArterial pressure, left ventricular mass, and aldosterone in essential hypertensionHypertension200137384585011244006
   PubMed Web of Science ®Google Scholar
• RochaRFunderJWThe pathophysiology of aldosterone in the cardiovascular systemAnn N Y Acad Sci20029708910012381544
   PubMed Web of Science ®Google Scholar
• BlasiERRochaRRudolphAEBlommeEAPollyMLMcMahonEGAldosterone/salt induces renal inflammation and fibrosis in hypertensive ratsKidney Int20036351791180012675855
   PubMed Web of Science ®Google Scholar
• RossiGPCesariMPessinaACLeft ventricular changes in primary aldosteronismAm J Hypertens2003161969812517694
   PubMed Web of Science ®Google Scholar
• DartschTFischerRGapelyukAAldosterone induces electrical remodeling independent of hypertensionInt J Cardiol2013164217017821764470
   PubMed Web of Science ®Google Scholar
• RossiGPSecciaTMGallinaVProspective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY study): rationale and study designJ Hum Hypertens201327315816322718050
   PubMed Web of Science ®Google Scholar
• RossiGPBolognesiMRizzoniDVascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patientsHypertension20085151366137118347224
   PubMed Web of Science ®Google Scholar
• Martinez-AguayoACarvajalCACampinoCPrimary aldosteronism and its impact on the generation of arterial hypertension, endothelial injury and oxidative stressJ Pediatr Endocrinol Metab201023432333020583536
   PubMed Web of Science ®Google Scholar
• FarquharsonCAStruthersADSpironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failureCirculation2000101659459710673249
   PubMed Web of Science ®Google Scholar
• RochaRStierCTJrPathophysiological effects of aldosterone in cardiovascular tissuesTrends Endocrinol Metab200112730831411504670
   PubMed Web of Science ®Google Scholar
• RochaRRudolphAEFrierdichGEAldosterone induces a vascular inflammatory phenotype in the rat heartAm J Physiol Heart Circ Physiol20022835H1802H181012384457
   PubMed Web of Science ®Google Scholar
• TakedaYRole of cardiovascular aldosterone in hypertensionCurr Med Chem Cardiovasc Hematol Agents20053326126615974890
   PubMedGoogle Scholar
• Yugar-ToledoJCBonalume-TacitoLHFerreira-MeloSELow-renin (volume dependent) mild-hypertensive patients have impaired flow-mediated and glyceryl-trinitrate stimulated vascular reactivityCirc J200569111380138516247215
   PubMed Web of Science ®Google Scholar
• SchiffrinELEffects of aldosterone on the vasculatureHypertension200647331231816432039
   PubMed Web of Science ®Google Scholar
• RuilopeLMAldosterone, hypertension, and cardiovascular disease: an endless storyHypertension200852220720818559719
   PubMed Web of Science ®Google Scholar
• CalhounDANishizakaMKZamanMAThakkarRBWeissmannPHyperaldosteronism among black and white subjects with resistant hypertensionHypertension200240689289612468575
   PubMed Web of Science ®Google Scholar
• GallayBJAhmadSXuLToivolaBDavidsonRCScreening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratioAm J Kidney Dis200137469970511273868
   PubMed Web of Science ®Google Scholar
• StrauchBZelinkaTHampfMBernhardtRWidimskyJJrPrevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe regionJ Hum Hypertens200317534935212756408
   PubMed Web of Science ®Google Scholar
• EideIKTorjesenPADrolsumABabovicALilledahlNPLow-renin status in therapy-resistant hypertension: a clue to efficient treatmentJ Hypertens200422112217222615480108
   PubMed Web of Science ®Google Scholar
• KayserSCDekkersTGroenewoudHJStudy heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysisJ Clin Endocrinol Metab201610172826283527172433
   PubMed Web of Science ®Google Scholar
• CalhounDAJonesDTextorSResistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure ResearchCirculation200811725e510e52618574054
   PubMed Web of Science ®Google Scholar
• PimentaEGaddamKKPratt-UbunamaMNAldosterone excess and resistance to 24-h blood pressure controlJ Hypertens200725102131213717885558
   PubMed Web of Science ®Google Scholar
• SiddiquiMCalhounDARefractory versus resistant hypertensionCurr Opin Nephrol Hypertens2017261141927798457
   PubMed Web of Science ®Google Scholar
• MartinsLCFigueiredoVNQuinagliaTCharacteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffnessJ Hum Hypertens201125953253820927128
   PubMed Web of Science ®Google Scholar
• de FariaAPDemacqCFigueiredoVNHypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertensionHypertens Res201336121067107223966059
   PubMed Web of Science ®Google Scholar
• SabbatiniARFariaAPBarbaroNRDeregulation of adipokines related to target organ damage on resistant hypertensionJ Hum Hypertens201428638839224284384
   PubMed Web of Science ®Google Scholar
• MenonDVArbiqueDWangZAdams-HuetBAuchusRJVongpa-tanasinWDifferential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patientsJ Clin Endocrinol Metab20099441361136619158191
   PubMed Web of Science ®Google Scholar
• ModoloRde FariaAPAlmeidaAMorenoHResistant or refractory hypertension: are they different?Curr Hypertens Rep2014161048525139782
   PubMed Web of Science ®Google Scholar
• AcelajadoMCPisoniRDudenbostelTRefractory hypertension: definition, prevalence, and patient characteristicsJ Clin Hypertens (Greenwich)201214171222235818
   PubMed Web of Science ®Google Scholar
• BrambillaGBombelliMSeravalleGPrevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE studyJ Hypertens201331102018202423838657
   PubMed Web of Science ®Google Scholar
• StaessenJLijnenPFagardRVerschuerenLJAmeryARise in plasma concentration of aldosterone during long-term angiotensin II suppressionJ Endocrinol19819134574657035596
   PubMed Web of Science ®Google Scholar
• Ubaid-GirioliSde SouzaLAYugar-ToledoJCAldosterone excess or escape: treating resistant hypertensionJ Clin Hypertens (Greenwich)200911524525219534021
   PubMed Web of Science ®Google Scholar
• SchjoedtKJAndersenSRossingPTarnowLParvingHHAldo-sterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rateDiabetologia200447111936193915551047
   PubMed Web of Science ®Google Scholar
• TomaschitzARitzEPieskeBAldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular diseaseMetabolism2014631203124095631
   PubMed Web of Science ®Google Scholar
• GaddamKKNishizakaMKPratt-UbunamaMNCharacterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansionArch Intern Med2008168111159116418541823
   PubMedGoogle Scholar
• TalerSJTextorSCAugustineJEResistant hypertension: comparing hemodynamic management to specialist careHypertension200239598298812019280
   PubMed Web of Science ®Google Scholar
• RossiGPSacchettoAVisentinPChanges in left ventricular anatomy and function in hypertension and primary aldosteronismHypertension1996275103910458621194
   PubMed Web of Science ®Google Scholar
• NishimuraMUzuTFujiiTCardiovascular complications in patients with primary aldosteronismAm J Kidney Dis199933226126610023636
   PubMed Web of Science ®Google Scholar
• SchlaichMPSchobelHPHilgersKSchmiederREImpact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjectsAm J Cardiol200085101199120610802001
   PubMed Web of Science ®Google Scholar
• MatsumuraKFujiiKOnikiHOkaMIidaMRole of aldosterone in left ventricular hypertrophy in hypertensionAm J Hypertens2006191131816461184
   PubMed Web of Science ®Google Scholar
• CatenaCColussiGNadaliniECardiovascular outcomes in patients with primary aldosteronism after treatmentArch Intern Med20081681808518195199
   PubMedGoogle Scholar
• CatenaCColussiGMarzanoLSechiLAAldosterone and the heart: from basic research to clinical evidenceHorm Metab Res201244318118722095099
   PubMed Web of Science ®Google Scholar
• BrillaCGWeberKTMineralocorticoid excess, dietary sodium, and myocardial fibrosisJ Lab Clin Med199212068939011453111
   PubMed Web of Science ®Google Scholar
• YoungMHeadGFunderJDeterminants of cardiac fibrosis in experimental hypermineralocorticoid statesAm J Physiol19952694 Pt 1E657E6627485478
   PubMedGoogle Scholar
• ChhokarVSSunYBhattacharyaSKHyperparathyroidism and the calcium paradox of aldosteronismCirculation2005111787187815710759
   PubMed Web of Science ®Google Scholar
• LawPHSunYBhattacharyaSKChhokarVSWeberKTDiuretics and bone loss in rats with aldosteronismJ Am Coll Cardiol200546114214615992648
   PubMed Web of Science ®Google Scholar
• ManieroCFassinaASecciaTMMild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronismJ Hypertens201230239039522179087
   PubMed Web of Science ®Google Scholar
• TomaschitzARitzEPieskeBAldosterone and parathyroid hormone: a precarious couple for cardiovascular diseaseCardiovasc Res2012941101922334595
   PubMed Web of Science ®Google Scholar
• ZhangYFengBAssociation of serum parathyrine and calcium levels with primary aldosteronism: a meta-analysisInt J Clin Exp Med201589146251463326628945
   PubMed Web of Science ®Google Scholar
• GoodfriendTLCalhounDAResistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapyHypertension200443351852414732721
   PubMed Web of Science ®Google Scholar
• PackAIGislasonTObstructive sleep apnea and cardiovascular disease: a perspective and future directionsProg Cardiovasc Dis200951543445119249449
   PubMed Web of Science ®Google Scholar
• GonzagaCCGaddamKKAhmedMISeverity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertensionJ Clin Sleep Med20106436336820726285
   PubMed Web of Science ®Google Scholar
• WehlingMEffects of aldosterone and mineralocorticoid receptor blockade on intracellular electrolytesHeart Fail Rev2005101394615947890
   PubMed Web of Science ®Google Scholar
• SowersJRWhaley-ConnellAEpsteinMNarrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertensionAnn Intern Med20091501177678319487712
   PubMed Web of Science ®Google Scholar
• Ehrhart-BornsteinMLamounier-ZepterVSchravenAHuman adipocytes secrete mineralocorticoid-releasing factorsProc Natl Acad Sci U S A200310024142111421614614137
   PubMed Web of Science ®Google Scholar
• KathiresanSLarsonMGBenjaminEJClinical and genetic correlates of serum aldosterone in the community: the Framingham Heart StudyAm J Hypertens2005185 Pt 165766515882548
   PubMed Web of Science ®Google Scholar
• FontanaVde FariaAPBarbaroNRModulation of aldosterone levels by −344 C/T CYP11B2 polymorphism and spironolactone use in resistant hypertensionJ Am Soc Hypertens20148314615124388430
   PubMed Web of Science ®Google Scholar
• SookoianSGianottiTFGonzalezCDPirolaCJAssociation of the C-344T aldosterone synthase gene variant with essential hypertension: a meta-analysisJ Hypertens200725151317143166
   PubMed Web of Science ®Google Scholar
• TakeuchiFYamamotoKKatsuyaTReevaluation of the association of seven candidate genes with blood pressure and hypertension: a replication study and meta-analysis with a larger sample sizeHypertens Res201235882583122456346
   PubMed Web of Science ®Google Scholar
• DaviesEHollowayCDIngramMCAldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2Hypertension199933270370710024332
   PubMed Web of Science ®Google Scholar
• RitterAMFontanaVFariaAPAssociation of mineralocorticoid receptor polymorphism I180V with left ventricular hypertrophy in resistant hypertensionAm J Hypertens201629224525026049084
   PubMed Web of Science ®Google Scholar
• CalhounDAWhiteWBEffectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertensionJ Am Soc Hypertens20082646246820409927
   PubMed Web of Science ®Google Scholar
• WilliamsBMacDonaldTMMorantSSpironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialLancet2015386100082059206826414968
   PubMed Web of Science ®Google Scholar
• CalhounDALow-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertensionJ Clin Hypertens (Greenwich)200791 Suppl 1192417215651
   PubMedGoogle Scholar
• ChapmanNDobsonJWilsonSEffect of spironolactone on blood pressure in subjects with resistant hypertensionHypertension200749483984517309946
   PubMed Web of Science ®Google Scholar
• PimentaECalhounDATreatment of resistant hypertensionJ Hypertens201028112194219520948392
   PubMed Web of Science ®Google Scholar
• ColussiGCatenaCSechiLASpironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertensionJ Hypertens201331131523011526
   PubMed Web of Science ®Google Scholar
• CatenaCColussiGSechiLAMineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new eraEur J Endocrinol20131681C1C523082005
   PubMed Web of Science ®Google Scholar
• NishizakaMKZamanMACalhounDAEfficacy of low-dose spironolactone in subjects with resistant hypertensionAm J Hypertens20031611 Pt 192593014573330
   PubMed Web of Science ®Google Scholar
• SartoriMCaloLAMascagnaVAldosterone and refractory hypertension: a prospective cohort studyAm J Hypertens200619437338016580572
   PubMed Web of Science ®Google Scholar
• LaneDAShahSBeeversDGLow-dose spironolactone in the management of resistant hypertension: a surveillance studyJ Hypertens200725489189417351384
   PubMed Web of Science ®Google Scholar
• GaddamKKPratt-UbunamaMNCalhounDAAldosterone antagonists: effective add-on therapy for the treatment of resistant hypertensionExpert Rev Cardiovasc Ther20064335335916716096
   PubMedGoogle Scholar
• PimentaECalhounDAResistant hypertension and aldosteronismCurr Hypertens Rep20079535335918177580
   PubMed Web of Science ®Google Scholar
• JansenPMDanserAHImholzBPvan den MeirackerAHAldosterone-receptor antagonism in hypertensionJ Hypertens200927468069119516169
   PubMed Web of Science ®Google Scholar
• DasGDePAldosterone renin ratio in patients with resistant hypertensionQJM20101031189789920360029
   PubMed Web of Science ®Google Scholar
• WeinbergerMHRonikerBKrauseSLWeissRJEplerenone, a selective aldosterone blocker, in mild-to-moderate hypertensionAm J Hypertens200215870971612160194
   PubMed Web of Science ®Google Scholar
• KrumHNollyHWorkmanDEfficacy of eplerenone added to renin-angiotensin blockade in hypertensive patientsHypertension200240211712312154100
   PubMed Web of Science ®Google Scholar
• PittBReichekNWillenbrockREffects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy studyCirculation2003108151831183814517164
   PubMed Web of Science ®Google Scholar
• EpsteinMWilliamsGHWeinbergerMSelective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetesClin J Am Soc Nephrol20061594095117699311
   PubMed Web of Science ®Google Scholar
• SavoiaCTouyzRMAmiriFSchiffrinELSelective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patientsHypertension200851243243918195160
   PubMed Web of Science ®Google Scholar
• EguchiKKabutoyaTHoshideSIshikawaSKarioKAdd-on use of eplerenone is effective for lowering home and ambulatory blood pressure in drug-resistant hypertensionJ Clin Hypertens (Greenwich)201618121250125727296360
   PubMed Web of Science ®Google Scholar
• OuzanJPeraultCLincoffAMCarreEMertesMThe role of spironolactone in the treatment of patients with refractory hypertensionAm J Hypertens2002154 Pt 133333911991219
   PubMed Web of Science ®Google Scholar
• NarayanHWebbDJNew evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertensionCurr Hypertens Rep20161853427072827
   PubMed Web of Science ®Google Scholar
• SinnottSJTomlinsonLARootAAComparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: a systematic review and meta-analysisEur J Prev Cardiol201724322823827856806
   PubMed Web of Science ®Google Scholar
• GaddamKCorrosCPimentaERapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical studyHypertension20105551137114220351345
   PubMed Web of Science ®Google Scholar
• WithamMDGillespieNDStruthersADHyperkalemia after the publication of RALESN Engl J Med20043512324482450
   PubMedGoogle Scholar
• JuurlinkDNMamdaniMMLeeDSRates of hyperkalemia after publication of the Randomized Aldactone Evaluation StudyN Engl J Med2004351654355115295047
   PubMed Web of Science ®Google Scholar
• McMurrayJJAdamopoulosSAnkerSDESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012Eur J Heart Fail201214880386922828712
   PubMed Web of Science ®Google Scholar
• PittBBakrisGRuilopeLMDiCarloLMukherjeeRSerum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)Circulation2008118161643165018824643
   PubMed Web of Science ®Google Scholar
• JessupMAbrahamWTCaseyDE2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesCirculation2009119141977201619324967
   PubMed Web of Science ®Google Scholar
• EpsteinMCalhounDAAldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diureticsJ Clin Hypertens (Greenwich)201113964464821896143
   PubMed Web of Science ®Google Scholar
• LentiniSHeinigRKimmeskamp-KirschbaumNWensingGPharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone: results from first-in-man and relative bioavailability studiesFundam Clin Pharmacol201630217218426604072
   PubMed Web of Science ®Google Scholar
• BogmanKSchwabDDelporteMLPreclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)Hypertension201769118919627872236
   PubMed Web of Science ®Google Scholar
• CalhounDAWhiteWBKrumHEffects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trialCirculation2011124181945195521986283
   PubMed Web of Science ®Google Scholar
• ShibataHItohHMineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertensionAm J Hypertens201225551452322258336
   PubMed Web of Science ®Google Scholar
• KashiwagiYMizunoYHaradaESuppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazoneAm J Med Sci2013345649750023313950
   PubMed Web of Science ®Google Scholar
• LiuGZhengXXXuYLLuJHuiRTHuangXHEffect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysisJ Hum Hypertens201529315916625078487
   PubMed Web of Science ®Google Scholar
• DahalKKunwarSRijalJThe effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studiesAm J Hypertens201528111376138525801902
   PubMed Web of Science ®Google Scholar
• GuoHXiaoQClinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trialsInt J Clin Exp Med2015857270727826221266
   PubMed Web of Science ®Google Scholar
• HwangAYDaveCSmithSMTrends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014Hypertension20166861349135427777360
   PubMed Web of Science ®Google Scholar